Status:
RECRUITING
Efficacy and Safety Phase III Clinical Study of VC005 Tablets in Subjects With Active Ankylosing Spondylitis.
Lead Sponsor:
Jiangsu vcare pharmaceutical technology co., LTD
Conditions:
Active Ankylosing Spondylitis
Eligibility:
All Genders
18-70 years
Phase:
PHASE3
Brief Summary
This clinical trial is a multicenter, randomized, double-blind, controlled phase III clinical study.
Eligibility Criteria
Inclusion
- The subject understands and voluntarily signs the informed consent form (ICF) and is willing and able to comply with the study protocol;
- The subject is between 18 and 70 years of age (including borderline values) at the time of signing the ICF, regardless of gender;
- The subject has been diagnosed with AS according to the 1984 New York Revised Criteria for Ankylosing Spondylitis
Exclusion
- Those who may be allergic to VC005, similar drugs or their excipients.
- Individuals who have undergone organ transplantation in the past and require continuous use of immunosuppressants.
- Those who, for any reason, are considered by the investigator to be unsuitable for participation in this study.
Key Trial Info
Start Date :
December 26 2025
Trial Type :
INTERVENTIONAL
Allocation :
ESTIMATED
End Date :
August 30 2027
Estimated Enrollment :
420 Patients enrolled
Trial Details
Trial ID
NCT07172360
Start Date
December 26 2025
End Date
August 30 2027
Last Update
January 2 2026
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
Peking University People's Hospital
Beijing, Beijing Municipality, China